Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D5DE
|
|||
| Former ID |
DIB014787
|
|||
| Drug Name |
ALPRENOXIME HYDROCHLORIDE
|
|||
| Synonyms |
CDDD-1815; HGP-5; Alprenoxime hydrochloride; 1-(2-Allylphenoxy)-3-(isopropylamino)-2-propanone oxime monohydrochloride; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-2-propanone oxime monohydrochloride
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61; ICD-9: 365] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H23ClN2O2
|
|||
| Canonical SMILES |
CC(C)NCC(=NO)COC1=CC=CC=C1CC=C.Cl
|
|||
| InChI |
1S/C15H22N2O2.ClH/c1-4-7-13-8-5-6-9-15(13)19-11-14(17-18)10-16-12(2)3;/h4-6,8-9,12,16,18H,1,7,10-11H2,2-3H3;1H
|
|||
| InChIKey |
ZFLRDGZJSCQDSR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 121009-30-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-3 (ADRB3) | Target Info | Modulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Salivary secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta3 adrenergic receptor signaling pathway | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003470) | |||
| REF 2 | Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent. Pharm Res. 1991 Nov;8(11):1389-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.